ORGANIZATION

PhRMA Takes Issue with Japan Govt’s Overreliance on ICER, Proposes Point-Based Appraisal Framework

February 5, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Pharmaceutical Research and Manufacturers of America (PhRMA) is sounding an alarm over the Japanese government’s proposed cost-effectiveness assessment (CEA) scheme, arguing that it is overly reliant on the ICER (incremental cost-effectiveness ratio; costs per QALY gained), ignores other benefits…

To read the full story

EFPIA Japan Chief Says CEA Selection Criteria Mar Predictability, 5 Billion Yen Sales Threshold “Too Low”
February 19, 2019

ORGANIZATION

EFPIA Japan, Patient Groups Call for Stronger Health Literacy, PPI
December 22, 2025
JPMA Exec Renews Call for Simpler Drug Pricing System
December 19, 2025
JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…